Day: December 14, 2022

SHENZHEN, China, Dec. 14, 2022 (GLOBE NEWSWIRE) — Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading independent online insurance product and service platform in China, today announced that it has received a notification letter (the “Compliance Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (“Nasdaq”) dated December 13, 2022, informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). As previously announced, the Company was notified by Nasdaq on October 12, 2022, that the Company was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company’s American depositary shares (“ADSs”) was below US$1.00 per share for 30 consecutive business days. On December 13,...

Press release, Helsinki, 14 December 2022 at 10:45 AM (EET) Nexstim Receives an Order for Two NBT® Systems from Canada Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that it has received an order for two NBT® systems through Canadian Health Solutions (CHS), the Company’s distributor in Canada. In 2021, Nexstim announced having extended its agreement with distributor CHS for an additional five years. Nexstim’s NBT® system is cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in Canada. Dr. David Elias, CEO of the Canadian distributorship and head of Canadian Health Solutions Group, comments:  “An estimated 10 percent of Canadians use health services for mood and anxiety disorders annually. We are pleased to be the exclusive Canadian distributor...

Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test’s ongoing development and future launch into developing countries LONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has received $14.2M in grants from the Bill & Melinda Gates Foundation for ongoing development of its point of care molecular tuberculosis (TB) testing system. Used with the LumiraDx multi-assay Platform, the molecular TB test is being developed to provide highly accurate results at a low price at the point of care enabling clinicians to immediately commence appropriate treatment and patient management to maximize health outcomes and minimize further spread of infection. According to the World Health Organization’s...

                                  December 14, 2022 RCI Banque discloses Capital Requirements following the 2022 SREP draft decision As part of the 2022 exercise of the supervisory review and evaluation process (“SREP”), the European Central Bank has notified RCI Banque of its draft decision regarding the capital requirement the Bank must respect in 2023. As of January 1, 2023*, the Pillar 2 requirement (P2R) will be 2.01% compared to 2.05% in January 2022. Requirements linked to the provisioning old non-performing receivables1 has been reduced from 0.05% to 0.01%. RCI Banque did not exercise its “right to be heard” and no major change is expected in the final decision. Starting from January 1, 2023*, RCI Banque will be required to meet the following capital requirements:    Minimum capital requirements  Total Pillar...

Bank of Åland Plc Stock exchange release December 14, 2022, 9.55 EET Bank of Åland discontinues buy-backs of own shares On May 10, 2022, the Bank of Åland began acquisitions of the Bank’s own shares, as authorised by the Annual General Meeting (AGM) on March 30, 2022. The maximum number of shares that may be acquired on the basis of the Board’s acquisition decision, in one or more rounds, is 375,000 Series B shares, which is equivalent to 4.1 per cent of the total number of Series B shares and 2.4 per cent the total number of shares. The maximum amount that may be used for the buy-back is EUR 10,500,000. The Board of Directors of the Bank of Åland (Ålandsbanken) has decided to discontinue the acquisition of the Bank’s own Series B shares that has occurred as part of the Board’s decision on May 10, 2022, since the maximum amount of EUR...